Dr. Essink is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1212 S 185th Cir
Omaha, NE 68130Phone+1 402-358-0256Fax+1 844-587-1403
Summary
- Brandon Essink, MD is a family medicine specialist based in Omaha, NE. He is currently the Chief Physician Officer for Velocity Clinical Research, a global clinical research company. Dr. Essink is also skilled in healthcare research, healthcare policy, and rural health. His education and training include a BS from the University of Nebraska-Lincoln, an MD from the University of Nebraska College of Medicine, and a fellowship in Vascular and Interventional Radiology at the same institution. Dr. Essink has extensive professional experience, having held positions at Avera Creighton Hospital, Bryan Medical Center, and Meridian Clinical Research, LLC. He has specialization in endoscopy, emergency medicine, clinical research, telemedicine, and rural family medicine. His publications, primarily focusing on vaccine safety and immunogenicity, have been published in leading medical journals and have received citations. Additionally, Dr. Essink has been involved in multiple clinical trials related to the safety and immunogenicity of vaccines and diverse patient conditions like Hyperhidrosis and Osteoarthritis Pain.
Education & Training
- University of Nebraska Medical Center College of MedicineFellowship, Vascular and Interventional Radiology, 2003 - 2004
- University of Nebraska Medical Center College of MedicineResidency, Family Medicine, 2001 - 2003
- University of Nebraska College of MedicineClass of 2001
- University of Nebraska-LincolnBS, 1997
Certifications & Licensure
- GA State Medical License 2015 - 2026
- MD State Medical License 2020 - 2026
- NE State Medical License 2002 - 2026
- AZ State Medical License 2024 - 2025
- CO State Medical License 2024 - 2025
- IA State Medical License 2020 - 2025
- IN State Medical License 2024 - 2025
- American Board of Family Medicine Family Medicine
- Join now to see all
Clinical Trials
- Study of Diclofenac Capsules to Treat Osteoarthritis Pain Start of enrollment: 2011 Oct 01
- Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD) Start of enrollment: 2012 Feb 27
- Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain Start of enrollment: 2012 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.Brandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos
Human Vaccines & Immunotherapeutics. 2024-12-31 - Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.Dean Follmann, Xiaowei Wang, Lindsey R Baden, Hana M El Sahly, Brandon Essink
Open Forum Infectious Diseases. 2024-12-01 - 9 citationsSafety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.Christine A Shaw, Brandon Essink, Charles Harper, Runa Mithani, Archana Kapoor
The Journal of Infectious Diseases. 2024-09-23
Press Mentions
- mRNA Vaccine Hesitancy? Midwestern Trial Site Organization Running Multiple Competitive Phase 3 Vaccine TrialsJuly 8th, 2021
- Moderna Vaccine Shows 94.1% Efficacy in a Phase 3 Clinical TrialDecember 31st, 2020
- Peer-Reviewed Report on Moderna COVID-19 Vaccine PublishesDecember 30th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: